[Special Stock] Cellumed, Surgical Robot Software? Spinal Material Growth Expected Upward
Cellumed is showing strong performance. It appears to be influenced by news that domestic companies related to spinal surgery have consecutively obtained approval from the U.S. Food and Drug Administration (FDA).
As of 2:05 PM on the 30th, Cellumed is trading at 3,980 KRW, up 3.65% from the previous day.
Previously, Cellumed developed surgical robot software last year in collaboration with Curexo.
Additionally, with government support, they are developing a process that improves the production yield of bone morphogenetic protein (BMP2) by more than five times compared to before. BMP2 is a growth factor that accelerates bone regeneration when applied to damaged areas such as the spine and teeth. The global market size is estimated to reach approximately 1 trillion KRW.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- Businessman Sentenced to 3 Years for Embezzling 6.6 Billion Won to a 'Virtual Shaman'
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
Recently, Curexo's spinal surgery robot, Qsys Spine, a renewed product, also received FDA approval. Qsys Spine is a spinal surgery robot that guides and fixes spinal pedicle screws to precise locations. It is expected that the market share of domestic products in the overseas spinal medical device market will increase.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
